Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CEO’ operating in the Medical space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Hari Sundram
Chief Executive Officer of Radion Health
Follow Hari Sundram:
About QMedic, Radion Health: Radion Health offers turnkey stop-loss solutions to brokers, consultants, and TPAs.
_______
Alexander Isakov
Founder & CEO of Lattis Surgical
Follow Alexander Isakov:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Paul Chang
President, CEO/CSO and Lead Founder of ARase Therapeutics
Follow Paul Chang:
About ARase Therapeutics: Arase Therapeutics is a science-focused oncology company developing therapies that modulate cancer-relevant cell signaling pathways.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Daniel Grau
President, Chief Executive Officer, and Director of Sojournix
Grau co-founded and has served as Chief Executive Officer and Director at Sojournix since 2016. An experienced biotech entrepreneur and operating executive, Mr. Grau led the deal to acquire SJX-653 and has driven the rapid growth and financing of the company from startup to clinical-stage pharmaceutical business. Prior to Sojournix, Mr. Grau served as President at Heptares Therapeutics (acquired 2015), Chief Executive Officer at Cortria (acquired 2010), and Chief Operating Officer at CombinatoRx (IPO 2005). Mr. Grau currently serves as an advisor to HotSpot Therapeutics and previously served as a member of the Product Advisory Board at Concert Pharmaceuticals and as an advisor to Nimbus Therapeutics. Earlier in his career, Mr. Grau worked with multi-national pharma companies as a management consultant focused on corporate and business franchise strategy, M&A, and new product launches. Mr. Grau earned his M.Phil., M.A., and M.A.R. degrees from Yale University, where he was awarded a Mellon Fellowship, the Day Graduate Prize, and a Bass Fellowship, and a B.A. with High Honors from Davidson College, where he held a Dana Honor Scholarship, a Montgomery Scholarship, and was elected to Phi Beta Kappa.
Follow Daniel Grau:
About Cortria Corporation, Heptares Therapeutics, Sojournix: Sojournix is a biotechnology company developing innovative medicines for women’s health and endocrine disorders.
Jeff Albers
Chief Executive Officer of Blueprint Medicines
Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.
Follow Jeff Albers:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Jason Krantz
CEO of Definitive Healthcare
Jason Krantz is Founder & CEO at Definitive Healthcare.
Follow Jason Krantz:
About Definitive Healthcare, Energy Acuity: Definitive Healthcare aims to transform data, analytics and expertise into healthcare commercial intelligence.
Harel Gadot
Co-Founder & CEO of Microbot Medical
Harel Gadot is a co-founder of Microbot Medical and has been serving as the CEO since its inception and the Chairman of the Board since 2013. He is also the Chairman of XACT Robotics Ltd., another promising medical robotics company, specializing in the field of needle steering for medical procedures such as biopsies. Until 2013, he was a board member at ConTIPI Ltd. Which was acquired in 2012 by Kimberly Clark. Prior to founding Microbot Medical, he served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenues and new product launches. Prior to this, Harel held several management positions in marketing and sales at Johnson & Johnson Medical Israel. He is a guest speaker for management and innovation courses at leading universities in the United States and Israel, and holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).
Follow Harel Gadot:
About MEDX Ventures Group, MEDX Xelerator, Microbot Medical: Microbot Medical is the first medical device company specialized in the researching, designing, developing and commercializing.
John McQuillan
CEO of Triumvirate Environmental
Follow John McQuillan:
About Triumvirate Environmental: Triumvirate Environmental provides enterprise waste management and environmental services to healthcare, education and industrial markets.
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Shantanu Gaur
Co-Founder & CEO of Allurion Technologies
Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scientific Officer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and significant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.
Follow Shantanu Gaur:
About Allurion Technologies, Genetic Alliance: Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Emad Rizk
President and Chief Executive Officer of R1 RCM
Emad Rizk currently serves as President and Chief Executive Officer of Accretive Health. He previously served as president of McKesson Health Solutions, a business unit of McKesson Corporation, and as Senior Partner and Global Director, Medical Management/Pharmacy for Deloitte Consulting. He led the company’s medical cost and quality management practice. Previous to that, he held a variety of roles at Monsanto Corporation, serving as Associate Medical Director, Corporate Medical and Scientific Affairs and then Worldwide Medical Director. Emad Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health. A Senior Scholar professor at Jefferson Medical College, Emad Rizk’s work has been widely published in medical journals and medical books. His book, The New Era of Healthcare: Practical Strategies for Providers and Payers, focuses on ways that providers and payers can work together to reduce costs while improving efficiency and patient care. In 2013, Modern Physician named Emad Rizk one of the “50 Most Influential Physician Executives in the United States,” the fifth time he has been recognized by this publication. In addition, Modern Healthcare has listed him among the “Top 100 Most Powerful People in Healthcare,” while Managed Healthcare Executive named him to its “Top 25 Leaders in Disease Management.” Emad Rizk has frequently lectured at Harvard, MIT, Wharton, Northwestern Kellogg School, and Columbia Business School.
Follow Emad Rizk:
About R1 RCM: R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models.
Ravi Ika
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
George Scangos
CEO of Vir Biotechnology
George A. Scangos, Ph.D., is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Follow George Scangos:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Michael T. Heffernan
President , CEO & Chairman of the Board of Collegium Pharmaceutical
Michael Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain. He was also previously the founder, President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses and was responsible for the spin-off of this business to create PreCision Dermatology. Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold. He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company. Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in a number of healthcare companies. He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company and PreCision Dermatology. Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
Follow Michael T. Heffernan:
About AvengeBio, Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Joseph Ciaffoni
President and Chief Executive Officer of Collegium Pharmaceutical
Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Joe Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Joe Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Joe Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.
Follow Joseph Ciaffoni:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Amarpreet Sawhney
CEO of Instylla
Amar is the President and CEO of Octux, Inc. a company focused on unmet needs in ophthalmic surgical wound closure and drug delivery. Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company. He was Chairman of marketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence. Before Confluent, Amar was the technology founder of Focal, Inc. (acquired by Genzyme). Amar’s innovations are the subject of almost 100 issued and pending patents. He is a board member of Soteira, Square One and TiE Boston. He is a board member and founder of Access Closure, Octux, Augmenix, and Incept LLC. Amar volunteers his time with entrepreneurial organizations including TiE Boston, MassMedic, and the E&Y Entrepreneur of the Year program. Amar and Confluent have been recognized with awards including MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, E&Y regional entrepreneur of the year award, Mass High Tech All Star award, and University of Texas Outstanding Young Engineering Graduate award. Amar holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.
Follow Amarpreet Sawhney:
About Incept, Instylla, SpaceOAR: Instylla’s focus is to leverage hydrogel technology .
Adam Sachs
Co-Founder and CEO of Vicarious Surgical
Follow Adam Sachs:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
William Herlands
CEO and Co-Founder of Willow
Will Herlands is the CEO of Willow. After graduating from Princeton University where he studied electrical engineering, Will worked at MIT Lincoln Laboratory conducting research on AI, robotics, and cybersecurity. He then entered a dual PhD in Machine Learning and Public Policy at Carnegie Mellon University, focused on helping policy makers and create more effective, intelligent, and just decisions. In 2017 he took these analytical approaches to help develop a novel way of providing stylish, affordable, and convenient adult incontinence products, allowing people to live proud and in style without losing their wallets.
Follow William Herlands:
About Willow: Willow is stylish, comfortable, affordable disposable underwear — delivered discreetly to your door at a fraction of the price.
Christopher McCann
CEO & Co-Founder of Current Health
I left school at the age of 16 and graduated with a Masters in Computer Science at age 21. At 20, I set up my first company, Dizeo – this was in social networking for children. This failed in 2011 but the experience taught me some of the most valuable lessons of my life. Around the same time, I was spending time in hospitals due to an unwell relative. I decided to go to medical school as a result in 2012. In 2014, I founded snap40 as a direct result of my experiences working in hospital. I was part of the care of patients who had deteriorated avoidably because the warning signs were detected late. I wanted a world where myself and my family would be treated preventatively at the earliest possible point. snap40 prevent illness by automatically detecting those at high risk. We’re a software company who uses our own wearable device, worn on the upper arm of the patient, to continuously monitor them. We then do predictive analytics to identify the patient who needs medical attention most and bring healthcare to them, far earlier. Please get in touch! E-mail: christopher@snap40.com
Follow Christopher McCann:
About Current Health: We help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.
Rushika Fernandopulle
Co-Founder & Chief Executive Officer of Iora Health
Rushika Fernandopulle is Co-founder and CEO at Iora Health
Follow Rushika Fernandopulle:
About Health Rosetta Group, Iora Health: Iora Health is a healthcare company that helps patients manage their health and navigate the healthcare system.
Stephane Bancel
President and Founding CEO of Moderna Therapeutics
Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs – founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc. Stephane was previously CEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company’s market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Follow Stephane Bancel:
About Flagship Pioneering, Moderna Therapeutics, Qiagen: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Scott Xiao
Co-Founder & CEO of Luminopia
Scott Xiao is the Co-Founder & CEO at Luminopia.
Follow Scott Xiao:
About Luminopia: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Kurt Graves
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Jonathan Bush
Founder and CEO of Zus Health
Jonathan Bush is the CEO and Founder of Zus Health. He is also the Chief Executive Officer, President, and Chairman of the Board of Directors. Mr. Bush co-founded athenahealth, Inc. in 1997 and has been a director since our inception. Prior to joining the Company, Mr. Bush served as an EMT for the City of New Orleans, was trained as a medic in the U.S. Army, and worked as a management consultant with Booz Allen & Hamilton. Mr. Bush obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an M.B.A. from Harvard Business School.
Follow Jonathan Bush:
About Firefly Health, Zus Health: Zus Health helps a new wave of healthcare builders to create technologies and services without the usual blockers.
Jason Fisherman
President & CEO of C4 Therapeutics
Follow Jason Fisherman:
About AlloMek Therapeutics, C4 Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Bill Gruber
President & CEO of Solace Therapeutics
Prior to this role as President and CEO of Solace Therapeutics, he co-founded Interlace Medical in August 2006 and served as their President and CEO until Interlace was acquired by Hologic in January 2011. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Prior to Interlace, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing. In this role, he was instrumental in creating Soteira, a Cortek subsidiary, focused on devices for treating vertebral compression fractures. Prior to Cortek, Bill spent 10 years at Boston Scientific Corporation. Before leaving Boston Scientific Corporation, he held the position of Director of the $172M Global Atherosclerotic Therapy business. Prior to entering the medical device sector, Bill spent five years in sales and marketing roles at Procter and Gamble.
Follow Bill Gruber:
About Solace Therapeutics: Solace Therapeutics develops and commercializes non-surgical office-based treatments for common bladder disorders.
Ronald Renaud
Chief Executive Officer of Translate Bio
Ronald Renaud has served as the President and chief executive officer of Idenix Pharmaceuticals, Inc. since October 2010. Prior to this, Ronald Renaud has served as the chief financial officer of Idenix Pharmaceuticals, Inc. since June 2007 and additionally as Chief Business Officer since June 2010. Ronald Renaud brings a unique mix of skills to this role with his finance experience at public biotechnology companies and on Wall Street, as well as his science background. Prior to joining Idenix, Ronald Renaud served as chief financial officer of Keryx Biopharmaceuticals. In this role he was responsible for the strategic planning and development of the finance function to support the company’s growth and its late-stage product candidate development. Prior to his position at Keryx, he spent several years as a senior biotechnology equity analyst for leading investment banks including Bear Stearns, Schwab SoundView and JP Morgan. Additional industry experience includes Mr. Renaud’s more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance. Ronald Renaud holds a Masters in Business Administration from the Marshall School of Business at the University of Southern California and a Bachelor of Arts from St. Anselm College in Manchester, NH.
Follow Ronald Renaud:
About Translate Bio: Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Paul Holzer
CEO and Co-Founder of XenoTherapeutics
Paul Holzer serves as CEO and co-founder of XenoTherapeutics. He is a scientist, engineer, and entrepreneur with over fifteen years of experience in various leadership and team management roles, and most recently in the fields of scientific research and new venture formation. Prior to founding XenoTherapeutics, Paul served as an Officer in the United States Navy SEAL Teams, with four decorated combat deployments to theatres such as Iraq, Afghanistan, and other undisclosed locations. He left the Navy in 2013 as a Lieutenant Commander (0-4) in the USNR.
Follow Paul Holzer:
About XenoTherapeutics: XenoTherapeutics is a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs.
Chen Schor
Co-Founder, President & CEO of resTORbio
Schor is a global healthcare industry leader with vast experience in pharmaceuticals, biotechnology, medical devices, business development and private equity. Schor has supported and helped build multiple healthcare companies and led multiple licensing, partnerships and M&A transactions with total value exceeding $8 billion with companies such as GSK, Amgen, Pfizer, Bayer, Teva and EMD-Serono. Prior to joining Novalere, Schor was VP Global Business Development with Teva Pharmaceuticals and had leadership roles at several emerging pharmaceutical and biotechnology companies. Schor was also a Partner at Yozma venture capital where he led the foundation and growth of multiple companies from inception to significant commercial success. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics, and is also a Certified Public Accountant (CPA).
Follow Chen Schor:
About Novalere FP, Predix Pharmaceuticals, resTORbio, Synta Pharmaceuticals: resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
Andrew Needleman
CEO & Founder of DoseSpot
Follow Andrew Needleman:
About Claricode, DoseSpot: E-Prescribing Integration Services
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Robert Coffin
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
David Coppins
Co-Founder and Chief Executive Officer of IntelyCare
David Coppins is co-founder and CEO of IntelyCare, the intelligent workforce management solution for post-acute healthcare facilities. Prior to starting IntelyCare, David served as president of Virgin Pulse, part of Sir Richard Branson’s Virgin Group. Before Virgin Pulse, David co-founded the college savings company Upromise in 1999. After Sallie Mae bought Upromise for $300M in 2006, David remained with the company and was later named CEO. Earlier in his career, David held various roles in business consulting and private equity at companies including Monitor Deloitte and Monitor Clipper Partners. David has a bachelor’s degree in business management from Brigham Young University.
Follow David Coppins:
About IntelyCare, Virgin Pulse: IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.
David Torchiana
President & CEO of Partners HealthCare
David F. Torchiana is Member of the Board of Directors, President & CEO at Partners HealthCare.
Follow David Torchiana:
About Partners HealthCare: Partners HealthCare was founded in 1994 by Brigham and Women’s Hospital and Massachusetts General Hospital.
Jeff Valk
Chief Executive Officer of Admetsys
Follow Jeff Valk:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Shawn Marcell
Co-Founder, President & CEO of Torus Biosystems
Follow Shawn Marcell:
About Torus Biosystems: Torus Biosystems is a biotech startup that delivers molecular diagnostics for infectious diseases.
Waleed Hassanein
President & CEO of TransMedics
Dr. Waleed Hassanein is president , CEO and director of TransMedics, Inc. He founded the company in August, 1998. As an experienced medical device executive, Waleed brings more than eleven years of experience in establishing and leading executive teams through the clinical development, market launch and commercial rollout of the company’s breakthrough Organ Care System (OCS™) technology in the European and US markets. Waleed has successfully raised >$120 million of private equity capital to develop and commercialize the OCS™ technology and has established world-class clinical advocates for the OCS™ technology world-wide from the key opinion leaders in organ transplantation. Waleed received his M.D. from Georgetown University where he also completed two years of General Surgery residency. He completed his pre-medical education from University of London and Cairo University School of Medicine.
Follow Waleed Hassanein:
About TransMedics: Transmedics is a medical device company involved in the design and production of transplant devices.
Jose Almeida
President and CEO of Baxter International
Jose Almeida is chairman and chief executive officer of Baxter International Inc. Prior to joining Baxter in October 2015, Almeida served as chairman, president and chief executive officer of Covidien plc from 2012 through 2015 and was named a director of the company in 2011. Almeida previously served as president of Covidien’s Medical Devices organization, where he oversaw several businesses accounting for approximately two-thirds of the company’s total annual revenues and approximately three-quarters of its operating profit. Almeida also served in several leadership roles at Covidien’s predecessor, Tyco Healthcare, including president of its worldwide medical device business and vice president of worldwide manufacturing. In addition to Covidien and Tyco, Almeida held leadership positions at Wilson Greatbatch Technologies, Inc., American Home Products’ Acufex Microsurgical division, and Johnson & Johnson’s Professional Products division. He began his career as a management consultant at Andersen Consulting (Accenture). Almeida served as chairman of the board of directors of Advamed from 2014 to 2015 and has been an active member of the AdvaMed board since 2005 and its executive committee since 2010. He also serves on the Board of Trustees of Partners in Health. A native of Brazil, Almeida received a bachelor’s of science degree in mechanical engineering from Escola de Engenharia Mauá in São Paulo.
Follow Jose Almeida:
About Baxter International, The Carlyle Group: Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people.
Robin Smith
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Paul Taheri
CEO of Yale Medical Group
Paul Taheri, MD, MBA, is Chief Executive Officer of Yale Medical Group (YMG), and a Deputy Dean at the Yale School of Medicine, providing leadership for a rapidly expanding physician organization that combines the best compassionate care with the latest in advancing medicine. He joined YMG from University of Vermont (UVM), where he was President and CEO of the UVM Medical Group in Burlington, and Senior Associate Dean for Clinical Affairs, as well as a professor of surgery. Before that he was Division Chief of Trauma, Burn and Critical Care, and then Vice Chair of Surgery at University of Michigan in Ann Arbor, where he completed his MBA at the Ross School of Business. Dr. Taheri, who is originally from Buffalo, N.Y., completed his medical degree at New York University and his general surgical residency at Tulane University. Yale Medical Group’s CEO is also the past chair of the Group on Faculty Practices for the Association of American Medical Colleges and an examiner for the American Board of Surgery. He has lectured broadly on various business topics, including cost of care, physician leadership and system optimizations.
Follow Paul Taheri:
About University of Vermont, Welsh, Carson, Anderson & Stowe, Yale Medical Group: Yale Medical Group is an academic multispecialty group that provides healthcare and medical services in the United States.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Rich Gliklich
Founder and CEO of OM1
Rich Gliklich is the Founder and CEO at OM1.
Follow Rich Gliklich:
About Cyft, OM1: OM1 is a healthcare technology company that leverages real-world clinical data for medical research and personalized medicine.
Earl Collier
CEO of 480 Biomedical
Earl M. (Duke) Collier, Jr. is Executive Chairman of Arsenal Medical and serves as CEO of 480 Biomedical. For many years, Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson (now Hogan Lovells) and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Earl Collier sits on the boards of 480 Biomedical, Arsenal Medical, Capricor, Transmedics and Newton-Wellesley Hospital. He earned a Bachelor of Arts at Yale University and received a law degree from the University of Virginia Law School.
Follow Earl Collier:
About 480 Biomedical: 480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
Jonathan Ng
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes is applying artificial intelligence-based precision medicine to gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD).
John Maraganore
CEO of Alnylam Pharmaceuticals
Chief Executive Officer & Director at Alnylam Pharmaceuticals.
Follow John Maraganore:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals, Third Rock Ventures: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Shrenik Jain
Founder & CEO of Marigold Health
Follow Shrenik Jain:
About Marigold Health: Marigold Health uses chat support groups to make substance use treatment more engaging and personalized for vulnerable populations.
Nathan Sigworth
Co-founder and CEO of PharmaCCX
Nathan was previously co-founder and CEO of PharmaSecure where he helped accelerate adoption of serialization as the standard in global pharmaceutical supply chain. Nathan is a graduate of Dartmouth College.
Follow Nathan Sigworth:
About PharmaCCX: We are a one-stop-shop for pharmaceutical companies and payers to negotiate, price, settle, and manage complex deals more efficiently.
Jayanthi Narasimhan
Founder & CEO of WatchRx
Follow Jayanthi Narasimhan:
About WatchRx: WatchRx connects patients, caregivers, and providers to improve medication adherence
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Nikin Tharan
CEO of Medsix
Nikin believes in using technology and leveraging existing resources to challenge the status-quo and impact lives. Nikin discovered he had a talent for electronics and started working at a lab affiliated with the Border Security Force in India at 9 y/o. He successfully piloted projects on agricultural management, anti-train collision, smart homes and got a honorable citation from the President of India. In his role as the President of WISE, Nikin improved STEM education at low-income schools in India through an innovative experiential education curriculum. Over the summer of 2015, he conducted an impact assessment of the non-profit with a research grant from Northeastern which helped WISE go national. Nikin got a full scholarship to attend Northeastern at 16 y/o. After the Harvard-MIT hackathon on iCorruption, he worked at Harvard Law School with Prof. Lawrence Lessig to research ways to reduce bias in academia. At HackingEDU 2015, he co-founded ITAP, a social enterprise that creates IT apprenticeship program for disadvantaged youth in the Bay Area. ITAP got selected for the Clinton Global Initiative University 2016, again in 2017, shortlisted for their Innovation Fund and secured a grant from Northeastern. For the latter half of 2016, Nikin was a Visiting Innovation Fellow at John Hancock’s Lab of Forward Thinking. In early 2017, he helped set up the world’s first open innovation platform with IoT at Northeastern. At MIT HackingMedicine, his team won two prizes and he co-founded Medsix, a medtech startup focused on post operative recovery management. After graduating, Nikin worked on commercializing the world’s first nanomaterial-based ion detector at Guardion and is an alumnae of the Techstars-US Air Force accelerator. He raised $250k for Medsix and now works there full-time. He enjoys reading, listening to podcasts, networking and being a mentor to millennial entrepreneurs.
Follow Nikin Tharan:
About Medsix: Novel wound drainage monitoring sensors + predictive tools for better patient outcomes
Namal Nawana
Chief Executive Officer of Smith & Nephew
Namal Nawana was appointed Chief Executive Officer and President and a Member of the Board of Directors of Alere in October 2014. He joined Alere in December 2012 as Chief Operating Officer to help drive the company to achieve financial strength and operational efficiency. Namal’s career experience has fueled a passionate belief that strategic innovation can achieve better access, quality and effectiveness of healthcare. In his current role, he is focused on unlocking the full potential of Alere’s assets and leveraging the company’s leadership in rapid diagnostics to develop solutions supporting each of these critical dimensions of healthcare. Mr. Nawana currently serves on the Board of Directors of AdvaMedDx, the industry association that advocates for the power of medical diagnostic tests to promote wellness, improve patient outcomes and advance public health globally; as well as the Board of Directors of Malaria No More, a global nonprofit with the mission to mobilize global resources required to achieve malaria eradication within the next 25 years. Before joining Alere, Namal held various global leadership roles during his 15-year tenure at Johnson & Johnson. He most recently served as Worldwide President of DePuy Synthes Spine, a Johnson & Johnson company. Prior to that role, Namal held general management positions spanning the globe, including Area Vice President for Johnson & Johnson Medical in Australia and New Zealand, Chairman of the DePuy Asia Pacific Franchise Council, General Manager for DePuy Australia and General Manager for DePuy Canada. In these roles, Namal drove continuous growth, innovation and profitability in a variety of specialties and technology fields. He also led diverse scientific and engineering functions as well as commercial operations during the 10-year period he spent living and working in Europe. Namal was born in Sri Lanka and raised in Australia. He holds an Honors degree in Mechanical Engineering and a Masters of Medical Science degree from the University of Adelaide and an MBA from the Henley Business School in the United Kingdom.
Follow Namal Nawana:
About Smith & Nephew: Smith and Nephew is a manufactures and markets orthopedic devices, sports medicine and ENT technologies.
Timothy Gregg Ferris
CEO of Massachusetts General Hospital
Timothy Gregg Ferris is the CEO of Massachusetts General Hospital.
Follow Timothy Gregg Ferris:
About Massachusetts General Hospital: Massachusetts General Hospital is the primary teaching hospital of Harvard Medical School and a biomedical research facility.
David Berry
Founder and CEO of Valo Health
David Berry, M.D., PhD., is an American inventor, entrepreneur, venture capitalist and CEO. Berry has co-founded and helped build over 10 companies in life sciences, technology, and sustainability. In 2007, he was named as the Innovator of the Year from the MIT Technology Review TR35 list of one of the top 35 innovators in the world under the age of 35. He was selected as a 2014 Young Global Leader by the World Economic Forum. In 2007, Berry founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. Berry served as President and CEO of the company through April 2009, and currently serves on the Board of Directors. Joule is pioneering solar fuels through a new technology that coverts sunlight, carbon dioxide, and salt water into drop-in fuels for prices as low as $20. In March 2010 and again in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2011. Joule’s unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule’s technology has now been successfully scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Berry has been recognized multiple times as one of the top people in bioenergy by Biofuels Digest. In 2009, Berry founded Pronutria, which is pioneering a new approach to unlock the vast untapped therapeutic potential of proteins in the diet. Berry served as President and CEO through March 2012. Pronutria has built a proprietary database that contains over 1 billion food proteins, and leverages 40 years of clinical data that validates the pharmacological activity of particular amino acid combinations to identify proteins that, when delivered orally, act as prodrugs. The protein delivery form allows for of important drug-like properties including pharmacokinetic control and improvement of physiochemical features. Pronutria has advanced two of its ProNutrein™ into clinical trials. In 2011, Berry founded Seres Health, a company that develops a new class of therapeutics based on insights into the biology of the human microbiome. Seres Health has developed a new approach to functionally assess the changes of the microbiome associated with disease, and identifies a consortia of organisms that can catalyze a shift to health. Seres has advanced is lead into the clinic for recurrent C. difficile. In 2005, Berry co-founded LS9, with Chris Somerville, Jay Keasling, and George M. Church, which uses synthetic biology to engineer microorganisms to covert sustainable, plant-based materials into low-carbon fuels and chemicals. LS9 has successfully built on technologies he invented with other co-founders to produce a scalable platform for renewable fules and chemicals. This technology was successfully scaled to a fully operational 135,000L facility in Okeechobee, Florida. The impact and importance of LS9’s technology led to its being named a Technology Pioneer by the World Economic Forum in 2008 and its being awarded the Presidential Green Chemistry Challenge Award in 2010, the U.S. Environmental Protection Agency’s highest environmental honor. LS9 was acquired by Renewable Energy Group in 2014. Berry joined Flagship Ventures, a Cambridge, Massachusetts based venture capital firm that invests in and founds companies in healthcare and sustainability, in 2005 where he is a Partner. Berry has been described “a rising star of the Boston-area venture capital scene,” and “one of the most brilliant thinkers.” Berry serves on the Board of Directors of Joule Unlimited, Seres Health, Pronutria, Eleven Biotherapeutics (NASDAQ: EBIO), and Symbiota. Berry has been an author of 14 scientific papers and over 60 patent applications.
Follow David Berry:
About Axcella, Evelo Biosciences, Flagship Pioneering, Hackley School, Indigo, Joule Unlimited Technologies, Omega Therapeutics, Seres Therapeutics, Seres Therapeutics, Valo Health: Valo Health uses human-centric data and machine learning-anchored computation to transform the drug discovery and development process.
Agneta Breitenstein
Founder & CEO of FOLX Health
A.G. is a co-founder of Humedica and serves as Chief Product Officer, Optum Analytics. Prior to Humedica, she was a Director at Leerink Swann, a leading health care investment bank. Previously, A.G. co-founded the Institute for Health Metrics (IHM). In 2000, she co-founded PrivaSource, which focused on the de-identification of health data. A.G. also served as Chair of the Massachusetts Work Group on the Privacy of Medical Records and was the primary drafter of the Massachusetts “Act to Protect the Privacy of Medical Records.” A.G. teaches ethics with Professor Marc Roberts at the Harvard School of Public Health. She received her MPH from Harvard University, her JD from the University of Connecticut, and her bachelor’s degree from Yale University.
Follow Agneta Breitenstein:
About FOLX Health: FOLX Health provides digital health care services designed for the LGBTQIA+ community.
Nagesh K. Mahanthappa
CEO of Scholar Rock
Nagesh Mahanthappa is a biotechnology entrepreneur with over 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock, Nagesh Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Nagesh Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.
Follow Nagesh K. Mahanthappa:
About Scholar Rock: Scholar Rock is discovering and developing a new class of biologic therapies.
Richard Labaudinière
CEO of Protego Biopharma
Richard Labaudiniere currently works as the Chief Executive Officer for Protego Biopharma.
Follow Richard Labaudinière:
About Protego Biopharma: Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy.
Michael Gilman
CEO of Arrakis Therapeutics
Michael Gilman, Ph.D. has served as a member of our board of directors since November 2013. Michael Gilman is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Michael Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Michael Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Michael Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Michael Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Michael Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of X4 Pharmaceuticals, Inc. and the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. Michael Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology.
Follow Michael Gilman:
About Arrakis Therapeutics, Obsidian Therapeutics: Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Michael Gilman
Chief Executive Officer of Arrakis Therapeutics
Follow Michael Gilman:
About Arrakis Therapeutics: Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
John Evans
Chief Executive Officer of Beam Therapeutics
John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals (AGIO), most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA (AG-221) and AG-120. He helped initiate and lead Agios’s landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple innovative research collaborations in cancer metabolism. He also initiated and co-led Agios’s strategic expansion into rare genetic diseases of metabolism. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals as program executive for the company’s Hsp90 inhibitors. He has also worked at McKinsey & Company (Pharmaceuticals practice), MedImmune, and Bayer Pharmaceuticals. Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
Follow John Evans:
About Beam Therapeutics: Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
John Evans
CEO of Beam Therapeutics
Follow John Evans:
About ARCH Venture Partners, Beam Therapeutics: Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Peter Van Haur
Chief Executive Officer of VitalConnect
Peter Van Haur is the Chief Executive Officer at VitalConnect.
Follow Peter Van Haur:
About VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Bernard Gordon
Founder, past chairman and CEO of Analogic
Bernard M. Gordon is the founder, past chairman and CEO of Analogic Corporation and Chairman Emeritus of the Board of Analogic. He holds more than 200 patents worldwide. A lifelong inventor, Mr. Gordon’s creations include the fetal monitor, the high-speed analog-to-digital converter, the instant imaging computer-aided tomography scanner, and Doppler radar. He is the primary architect of the multi-slice dual-energy computer tomography system that is the basis of the eXaminer 3DX 6000 Certified Explosive Detection System with over 1,000 units installed at airports worldwide. Mr. Gordon is often called the “father” of modern analog-to-digital conversion for his many contributions to the technology. Presently, he is Chairman of Photo Diagnostic Systems, Inc., involved in advanced imaging. He remains an active, entrepreneurial innovator. Mr. Gordon was awarded the National Medal of Technology by President Reagan in 1986 and elected to the National Academy of Engineering in 1991. He has been honored by the Engineering Societies of New England, the Institute of Electrical and Electronic Engineers, the Franklin Institute, the Museum of Science and Eta Kappa Nu, among others. He established the National Academy of Engineering’s Bernard M. Gordon Prize for Engineering Leadership Education. He holds B.S. and M.S. degrees from MIT and several honorary doctorate degrees in engineering and science.Bernard M. Gordon and the teams of engineers he has led have conceived, invented, and developed myriad pioneering high-technology instrumentation, medical imaging, security imaging, computer, aerospace telemetry and communications systems. Founder and Chairman Emeritus of the Board of Analogic Corporation, Bernard Gordon is often called the “father” of modern analog-to-digital conversion for his many contributions to the technologies that help enrich our lives. Presently, Chairman of Photo Diagnostic Systems, Inc., involved in advanced imaging, he remains an active, entrepreneurial innovator. Mr. Gordon has been awarded over 100 U.S. patents. Among his most significant patents are the first known Electronic Successive Approximation Analog-to-Digital Converters and Tomography Signal Processing Systems.From his earliest contributions to the development of UNIVAC – the world’s first commercial digital computer – and to the first alphanumeric dot matrix display, to scanning devices that would become the central core of modern medical imaging and counter-terrorism technology, Gordon has represented the key creative and essential role of the engineer in the development of new technology.Gordon was awarded the National Medal of Technology by President Reagan in 1986 and elected to the National Academy of Engineering in 1991. He has been honored by the Engineering Societies of New England, the Institute of Electrical and Electronic Engineers, the Franklin Institute, the Museum of Science and Eta Kappa Nu, among others. He established the National Academy of Engineering’s Bernard M. Gordon Prize for Engineering Leadership Education. He holds B.S. and M.S. degrees from MIT and several honorary doctorate degrees in engineering and science.Of particular relevance to this document is the fact that Gordon was the primary conceptual architect of the multi-slice dual-energy systems delivered to the TSA via L-3 Communications.
Follow Bernard Gordon:
About Analogic, Photo Diagnostic Systems: Analogic is a technology company that develops computed tomography, ultrasound, digital mammography, and magnetic resonance imaging systems.
Justin Hanes
Founder, Director & Former CEO of GrayBug
Justin Hanes received a B.S. in Chemical Engineering from UCLA in 1991 and Ph.D. in Chemical Engineering from MIT in 1996. He did postdoctoral training in Oncology and Neurosurgery at the Johns Hopkins University School of Medicine in 1996-1998. He is a full Professor at Johns Hopkins University, with appointments in the Departments of Ophthalmology, Biomedical Engineering, Chemical & Biomolecular Engineering, Environmental Health Sciences, Neurosurgery and Oncology. He is the Director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine, where he leads a laboratory of more than 40 scientists and engineers. He also serves on the Executive Committee and as Director of Therapeutics for the Institute for NanoBioTechnology at Johns Hopkins. He has published widely and is an inventor on more than 15 patent families, many of which have been licensed to industry. He has given more than 100 invited lectures and has received numerous honors and awards , including being named among the World’s Top 100 Young Innovators and Leaders in Technology and Business, by the MIT Technology Review in 2003. He was also named a Global Young Leader by the U.S. National Academy of Sciences, and selected as a representative of the U.S. to attend the Meeting of the New Champions at the World Economic Forum in Tianjin, China in 2008. He currently serves on the scientific advisory board for Genentech, Inc.’s Drug Delivery Division and is a founder and director of Kala Pharmaceuticals, where he also serves as the Chair of the Scientific Advisory Board.
Follow Justin Hanes:
About GrayBug, Johns Hopkins University School of Medicine, Kala Pharmaceuticals, Spiral Therapeutics, The Johns Hopkins University: GrayBug focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases.
Estuardo Aguilar-Cordova
Chairman and Chief Executive Officer of Candel Therapeutics
Estuardo Aguilar-Cordova is a co-founder of Candel Therapeutics and has been the chairman and CEO since 2002. He has more than 30 years of experience in the fields of biotherapeutics, cancer research and drug development, including serving as principal or co-investigator in more than 25 clinical trials ranging from Phase I to Phase III. Prior to moving into his role at Candel, Estuardo Aguilar-Cordova held academic positions for nearly two decades. Most recently, he was deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School in Boston and was a faculty member in Pediatrics, Hematology-Oncology at Baylor College of Medicine in Houston. He has served on many national oversight committees, including roles as chairman and member of the NIH Recombinant Advisory Committee (RAC), as a consultant to the FDA Biological Response Modifiers Advisory Committee (BRMAC), and as a member of the Vaccine and Related Products Advisory Committee (VRPAC). Estuardo Aguilar-Cordova has also held other appointments including president of the Latin American Gene Therapy Society. Estuardo Aguilar-Cordova has published more than 80 peer-reviewed scientific publications and book chapters, is on the editorial board of various professional journals and is an inventor on several patent applications. A native of Guatemala, Estuardo Aguilar-Cordova completed his undergraduate studies in Biology at California State University, Bakersfield; Medicine, at Universidad Francisco Marroquín in Guatemala City; and Ph.D. in Molecular Genetics at the University of California at Davis.
Follow Estuardo Aguilar-Cordova:
About Candel Therapeutics: Candel Therapeutics develops cancer immunotherapies designed to improve the lives of cancer patients and their families.
Kate Rumrill
President and CEO of Ablative Solutions
Kate brings 27 years of experience in the Medical Device and Pharmaceutical Industry. Previously she held the position of Vice President, Global Clinical and Medical Affairs at Covidien. She has extensive experience in product development in the CNS space through her time at Aspect Medical Systems and Eli Lilly & Company. Kate first joined NeoSync in 2010, leading the company’s clinical and regulatory activities, and later rejoined as President and CEO in April 2015. She holds a BS degree in both Biology and Psychology from the State University of New York.
Follow Kate Rumrill:
About Ablative Solutions: Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension.
Kevin Hershberger
President & Chief Executive Officer of Lumicell
Follow Kevin Hershberger:
About Lumicell: Lumicell is a biotechnology company that develops and markets image-guided cancer surgery solutions.
David Platt
CEO of Boston Therapeutics
David Platt, Ph.D., Boston Therapeutics founder and CEO.
Follow David Platt:
About BioXyTran, Boston Therapeutics, Oxygen Therapy: Boston Therapeutics develops and commercializes novel compounds for unmet medical needs in the areas of diabetes and inflammatory diseases.
Peter van der Sluis
President and CEO of Turnkey Health
Follow Peter van der Sluis:
About Turnkey Health: Turn·Key Health (“TKH”) offers solutions to select healthcare services providers .
Thomas Marchand
President & CEO of NIDO
Thomas Marchand is a French entrepreneur based in Boston, graduated by ESSEC Business School (Paris). His first company in the private lesson industry was acquired in 2014 by the market leader. Thomas founded then BIOMODEX and served five years as the CEO & Chairman. This medical device company is developing 3d Printed patient-specific anatomical models designed to provide a pre-operative planning solution to physicians in the neurovascular and structural heart space. He raised $20M+ and built a 40 people team in Paris and Boston, including a manufacturing facility in Massachusetts. BIOMODEX counts Medtronic, Stryker, Boston Scientific, and J&J as customers. Thomas recently joined NIDO as the President and CEO, co-founded by Pedro Del Nido, Chairman of cardiovascular surgery at Boston Children Hospital and Professor at Harvard Medical School. NIDO is developing SEPIA, an innovative solution designed to improve epicardial ablation efficiency and, ultimately, cure Ventricular Tachycardia. NIDO is targeting a clearance by the FDA in 2022 and starting commercialization the same year. Thomas has been granted French American Entrepreneur of the year 2016 and is a regular guest at the entrepreneurial finance program at Babson College.
Follow Thomas Marchand:
About NIDO: NIDO is a medical device company developing SEPIA, an Epicardial Ablation Solution for VT.
Stuart Randle
CEO of Ivenix
Stuart Randle has served as a Director since February 2006. Stuart presently serves as CEO of Ivenix, a privately held medical technology company. He also is a Director of Teleflex Inc. where he is a member of its Compensation Committee and Lead Independent Director of publicly traded biotechnology company FlexPharma, Inc. From 2004 – 2014, Stuart served as President, CEO and Director of GI Dynamics. Stuart was an Entrepreneur-in-Residence for Advanced Technology Ventures, a healthcare and IT venture capital firm. From 1998 to 2001, he was President, CEO and a director of Act Medical, Inc. Prior to ACT, Stuart was corporate officer at Allegiance Healthcare Corporation, where he was integral to the successful spin-off of Allegiance from Baxter International. Stuart started his career at Baxter Healthcare where he spent 10 years in various senior management positions. Stuart earned an MBA from The Kellogg Graduate School of Management at Northwestern University and a BS in Mechanical Engineering from Cornell University. He is a Trustee of the Cotting School, America’s first school for children with disabilities, and is a member of the Board of Directors of The Advanced Medical Technology Association (AdvaMed) and Teleflex, Inc
Follow Stuart Randle:
About Ivenix: Ivenix is a medical technology company that develops a next-generation infusion management system.
Rick Geoffrion
President and CEO of Cyrano Therapeutics
Rick Geoffrion is the President and CEO of Cyrano Therapeutics.
Follow Rick Geoffrion:
About Cyrano Therapeutics, The Mullings Group: Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.
Eddie Martucci
Co-Founder and CEO of Akili Interactive Labs
Dr. Martucci is a Senior Associate at PureTech Ventures, and is part of the founding team of Akili Interactive Labs, Appeering, and Vedanta Biosciences. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation. Dr. Martucci completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on the rational design of novel allosteric inhibitors for a pathogenic parasite. He led a research project that characterized a potential enzyme drug target and identified two novel chemical scaffolds as potent proof-of-concept compounds for novel antiparasitic therapy. During his graduate work, he received NIH training grants in both Chemical Biology and Parasitology. Dr. Martucci received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.
Follow Eddie Martucci:
About Akili Interactive Labs, PureTech Health: Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games.
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Ze Jiang
Founder/CEO of iQuartic
EHR systems and healthcare data expert (in processing and analyzing). Presented at clinical data and systems conferences, and consults healthcare organizations (esp. community based) on leveraging data and systems to advance care quality and financial health.
Follow Ze Jiang:
About iQuartic: iQUARTIC develops cloud-based platforms that eliminate traditional paper-based coding with easy-to-use web programs.
Steven L. Hoerter
President and CEO of Deciphera Pharmaceuticals
Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter’s 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.
Follow Steven L. Hoerter:
About Deciphera Pharmaceuticals: Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
Michael Maylahn
Founder & CEO of Stasis Labs
Michael Maylahn is the Founder & CEO at Stasis Labs.
Follow Michael Maylahn:
About Stasis Labs: Stasis has built a cloud-connected vital signs monitoring system that rescues the 11 million under-monitored patients around the world.
Cheri Walker
President & CEO of Rhinostics
Cheri Walker currently works as President and Chief Executive Officer at Rhinostics.
Follow Cheri Walker:
About Rhinostics: Rhinostics provides a novel solution of enabling comfortable sample collection, rapid accessioning, and automated cap removal.
Iain MacLeod
Co-Founder ,CSO & CEO of Aldatu Biosciences
Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy. Iain maintains an academic appointment at the Harvard School of Public Health AIDS Initiative. He undertook his post-doctoral training at the Harvard School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge (2008), an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.
Follow Iain MacLeod:
About Aldatu Biosciences, Harvard T.H. Chan School of Public Health: Aldatu Biosciences is changing infectious disease treatment paradigms through innovative diagnostic solutions.
Ed Damiano
President & CEO of Beta Bionics
Ever since his now 19-year-old son David developed type 1 diabetes at 11 months of age, Ed D. has been committed to creating and integrating closed-loop blood-glucose control technologies with a vision of building a bionic pancreas by the time his son headed off to college. Between 2005 and 2008, he and his PhD student, Firas El-Khatib, began conducting experiments in diabetic pigs in his laboratory at Boston University testing an early laptop-version of their bionic pancreas system. They then progressed with their clinical collaborators at the Massachusetts General Hospital to conduct over four years in-patient trials in adults and adolescents with T1D. Over the past five years, his team at Boston University, along with his clinical collaborators, have conducted over a dozen outpatient and home-use clinical trials in adults and children with type 1 diabetes testing a mobile version of their bionic pancreas, which ran on an iPhone. This effort ultimately led to the development of the iLet bionic pancreas system. In 2015, Ed and his wife Toby Milgrome, along with Firas El-Khatib and Ed and Serafina Raskin, founded Beta Bionics, Inc. as a Massachusetts public benefit corporation with the goal of bringing the iLet through final clinical trials, regulatory approval and into the hands of people with type 1 diabetes. Ed Damiano is a Professor of Biomedical Engineering at Boston University and has held that role since 2004. He is also President and CEO of Beta Bionics. His expertise and training are in the areas of mechanical and biomedical engineering and applied mathematics.
Follow Ed Damiano:
About Beta Bionics: Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet.
Trey Foskett
Co-Founder and CEO of Watchmaker Genomics
Trey Foskett is the Co-Founder and CEO of Watchmaker Genomics.
Follow Trey Foskett:
About Watchmaker Genomics: Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
Rahul Chaturvedi
CEO/ Founder of Clora
Rahul Chaturvedi is founder & CEO at Clora
Follow Rahul Chaturvedi:
About Biotech2050, Clora: Clora is an intelligent platform that matches life science companies with flexible, on-demand expertise.
Robert J. Mulroy
Chief Executive Officer of Partner Therapeutics
Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.
Follow Robert J. Mulroy:
About Partner Therapeutics: PTx is a biopharmaceutical company committed to the development and commercialization of therapies that improve the treatment of cancer.
John Lewandowski
CEO of Disease Diagnostic Group
John R. Lewandowski (Founder/CEO) is a PhD student at MIT in the Mechanosynthesis Group underneath Prof. John Hart, focusing on low-cost diagnostics leveraging the physics of microparticles, optics, magnetism, and self assembly. His interest in disease diagnostics goes back all the way to high school, where he was a two-time state champion in Disease Detectives in Science Olympiad. He graduated in 2012 from Case Western Reserve University with bachelor’s degrees in mechanical engineering, entrepreneurship, economics, and business management, continuing on with a Masters of Engineering and Management degree from CWRU. He has experience in medical device design and commercialization with internships at Cleveland Clinic, General Electric, CWRU, as well as a drug-delivery start-up Recon Therapeutics. He’s also been Managing Partner at Lew & Dowski Capital, LLC for the past four years, scaling a boutique investment fund based on an innovative supply and demand model in a niche market with a quickly growing NAV of $500,000. He has been recognized as a National Defense Science and Engineering Graduate Fellow, a NSF Graduate Research Fellow, a Hertz Foundation Fellowship Finalist, a Tata Fellow, a Don Richards Fellow, a Tau Beta Pi Fellow, a member of Phi Beta Kappa Society, a Forbes 30 under 30 nominee, distinguished in Think Magazine’s 30 under Thirty and Foreign Policy’s 100 Leading Thinkers, and a Lemelson-MIT Prize Inventor. He’s been an author on a dozen papers and holds one patent on drug reconstitution.
Follow John Lewandowski:
About Disease Diagnostic Group, Lew & Dowski Capital: DDG is a pre-revenue medical device company specializing in the development of rapid, accurate, and inexpensive disease diagnostic tests.
Abhishek Jain
CEO of Beacon Dental Partners
Abhishek Jain is the CEO & co-founder of Beacon Dental Partners, located in Massachusetts. At Beacon Dental Partners, Abhishek he is responsible for the oversight and management of all operations and day-to-day functions of all dental clinics. Prior to Beacon Dental Partners, Abhishek was the Founder of TiE Angels Boston, a diversified angel group that invest in start-ups in to Series A rounds. Abhishek has participated in multiple transaction with it’s personal capital. Investments (typically between between $200K-$1M) include Vizibility Inc, (Sold to All State Legal), AdverCar (still operating and growing). Today, TiE Angels is one of the largest angel groups in Boston. Abhishek has been recognized as the “50 Most Influential Indians in New England” by New England Business Journal. Prior to TiE Angels, Abhishek worked at Beacon Tree Capital, SetMeUp, The Blackstone Group, Bain & Company, and Goldman Sachs. Abhishek received his Bachelor’s degree from University of Southern California, where he graduated with honors and was a recipient of multiple prestigious scholarships and received his MBA from Harvard Business School.
Follow Abhishek Jain:
About Beacon Dental Partners: Dental service organization
Patrick Flanagan
Chief Executive Officer of Veristat
Patrick Flanagan is Chief Executive Officer at Veristat, responsible for the company’s’ business management and financial performance. In collaboration with company leaders, Patrick is responsible for the development and implementation of Veristat’s organizational goals and business strategies.Patrick has built a 23 year career over multiple decades leading commercial growth, international expansion and financial & operational improvement initiatives for leading companies in the consulting, healthcare, and software fields including A.T. Kearney, Baxter International, Allegiance Healthcare and Oracle. Prior to joining Veristat, Patrick served as Chief Operating Officer of Certara and the General Manager of Certara’s Pharsight Consulting Services Group, a Vector Capital portfolio company engaged in the business of providing consulting services and software to pharmaceutical and biotechnology companies.Patrick holds a BS in Business from Penn State University and an MBA with a concentration in Finance and Marketing from the Kellogg Graduate School of Management at Northwestern University. Patrick is also an active father, skier, golfer, occasional marathon runner and aging tri-athlete.
Follow Patrick Flanagan:
About Veristat: Veristat, a full service Clinical Research Organization (CRO).
Ranjit Makam
Founder & CEO of Medpick
Ranjit Makam is the Founder and CEO at Medpick.
Follow Ranjit Makam:
About Medpick: Medpick intends to simplify healthcare services from the limitations of obtaining medications, health & wellness supplies, & beauty care.
Glenn Larsen
Co-Founder, President & CEO of Aquinnah Pharmaceuticals
Glenn Larsen is a Co-Founder, President & Chief Executive Officer at Aquinnah Pharmaceuticals since 2014. Aquinnah is a pharmaceutical company focused on the development of new therapies for ALS and neurodegenerative diseases. Glenn brings significant experience from his tenure in the discovery, development and commercialization of pharmaceutical, biotech and regenerative medicines, including raising approximately $65 million in private venture funding. Glenn has been closely involved with the commercial registration of five biologics and led teams that advanced over 15 new biologic and small molecule chemical entities to clinical development. Previously, Glenn was the Vice President of Musculoskeletal Sciences at Wyeth (Pfizer); directing R&D in the fields of arthritis, pain, inflammation and tissue regeneration, including responsibility for the global development and commercial efforts of Enbrel, an anti-TNF therapeutic. Glenn also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration programs. Glenn currently serves on the Board of Directors of Aquinnah Pharmaceuticals, Anika Therapeutics, 180 Therapeutics and previously Hydra Biosciences; and has held prior senior executive leadership roles at Hydra Biosciences and SpringLeaf Therapeutics. Glenn received his Ph.D. in Biochemistry from Stony Brook University and is a PMD Graduate of Harvard Business School.
Follow Glenn Larsen:
About Aquinnah Pharmaceuticals: Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
John Vacha
President & CEO of Intact Medical
Follow John Vacha:
About Intact Medical: Intact Medical develops and markets minimally invasive systems for diagnostic and therapeutic applications for cancer.
Barbara Weber
CEO & President of Tango Therapeutics
Barbara Weber joined Third Rock Ventures in 2015 to focus on oncology research and development opportunities throughout the portfolio. Barbara brings over 25 years of experience working in oncology research, in which time she has been widely published and received numerous academic and research awards for her work. Barbara has spent the last six years at Novartis, where she held the position of senior vice president and global head of oncology translational medicine. In this role, she was responsible for early clinical and translational scientific functions, including trial design and execution, implementation of patient selection strategies and continuation of translational support through full development. Prior to joining Novartis, Barbara served as vice president of three groups at GlaxoSmithKline, including Global Biomarkers, Oncology Discovery and Translational Medicine, and Cancer Metabolism Drug Discovery. Until 2005, Barbara was a professor of medicine and genetics at The University of Pennsylvania School of Medicine, heading a clinical and translational research program in cancer genetics and the UPenn Cancer Center Breast Cancer program. Barbara is a member of honorary societies such as the American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara has also served on various scientific advisory boards and on the board of directors of both the American Society of Clinical Oncology and the American Association of Cancer Research. Barbara is a graduate of the University of Washington School of Medicine. She completed her residency in internal medicine at Yale University School of Medicine and her fellowship in medical oncology at the Dana-Farber Cancer Institute. Barbara has received two standing ovations in her life – most notably from an entire restaurant after eating every bite of an apple pie.
Follow Barbara Weber:
About Tango Therapeutics, Third Rock Ventures: Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Charles Wilson
President and CEO of Cogent Biosciences
Charles Wilson is the president and chief executive officer of [Unum Therapeutics](https://www.crunchbase.com/organization/unum-therapeutics#/entity), a cancer cell therapy company that offers a platform to couple tumor-specific antibodies with the body’s own immune system. Prior to that, he was the vice president and head of global strategic alliance at Novartis. Before joining Novartis, Wilson co-founded and served as the chief technology officer of Archemix. Wilson obtained his bachelor’s degree in chemistry and master’s degree in cell biology from Boston University. He also holds a PhD in biophysics from the University of California, San Francisco. Wilson is based in Boston, Massachusetts, United States.
Follow Charles Wilson:
About Cogent Biosciences: Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Caroline Loew
President & Chief Executive Officer of Glympse Bio
Caroline Loew is the President and Chief Executive Officer at Glympse Bio.
Follow Caroline Loew:
About Glympse Bio: Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Todd Krueger
President & CEO of AOBiome
Todd Krueger is the Chief Executive Officer, President and a Director of our Company. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Northwestern University, United States, with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University, United States. Prior to joining us, Mr. Krueger had over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008)), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform. Mr. Krueger also currently serves as a director of General Automation Laboratory Technologies, Inc. (GALT), a microbiome tools company based in the United States.
Follow Todd Krueger:
About AOBiome: AOBiome is a life sciences company that focuses on transforming human health.
William T. Sharp
Co-founder, Chairman and Chief Executive Officer of DxNow
Three decades of executive, general management, business development, sales, marketing, and technology commercialization experience in career spanning private venture-backed businesses, mid-size, and Fortune 100 public companies in the medical device, diagnostics, and life science tools and services markets. Bill has served in senior leadership roles with five venture-backed companies – as CEO of CYTOO, Inc. & ArunA Biomedical, CCO of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen). Earlier career includes leadership roles with Life Technologies, General Manager of Terumo Medical, VP of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Earned M.S. and B.A. degrees from the Pennsylvania State University.
Follow William T. Sharp:
About DxNow: DxNow™ is a privately held company located in the Boston area leveraging advanced microfluidic and imaging technologies
Robert Connelly
CEO of Elicio Therapeutics
Robert joined as Venture Partner with Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is also the CEO of Pronutria, a pioneer in protein-based therapeutic nutrients and founded within Flagship’s VentureLabs innovation foundry. He has 30+ years of experience starting, financing, building and managing companies in the life sciences, food and beverage, and nutrition industries. He is the former CEO of Domantis, Pulmatrix, and WikiCell Designs. Robert began his career with the Medical Diagnostics Division of Abbott Laboratories, spending 11+ years in sales, marketing and management positions. After leaving Abbott, he spent six years with BioVeris, (formerly IGEN International; acquired by Roche) in the roles of SVP of Sales and Marketing and General Manager of IGEN’s Life Sciences unit. Robert led IGEN’s efforts to develop, market and license novel detection technologies utilized in medical diagnostics and drug discovery, and had a central role in IGEN’s financing activities. In 2000, Robert became the founding CEO and first employee of Domantis, a private UK-based biotechnology company founded by world-renowned scientist entrepreneurs Ian Tomlinson and Greg Winter. Domantis created a novel fully-human antibody fragment platform, growing into a 75-person organization with operations in the UK and USA, 13 novel therapeutic programs, and seven therapeutic partnerships before selling the company to Glaxo SmithKline for $454 million in cash, the largest all-cash valuation paid for a preclinical biotechnology company. In 2007, Robert was appointed CEO of Pulmatrix, a private pharmaceutical company developing inhaled drugs for respiratory diseases. In 2012, he co-founded WikiCell Designs with Pulmatrix Founder David Edwards to develop deliciously edible forms of packaging that enclose food or drinks in ways similar to how nature protects foods such as grapes, oranges, or coconuts. Robert has raised over $135 million in venture capital financing for his companies, closed numerous transactions including license, platform technology, drug discovery, co-development, government and foundation funding, and M&A partnerships and has launched many innovative products during his career.
Follow Robert Connelly:
About Elicio Therapeutics, WikiCell Designs: Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Maya R. Said
CEO and Co-Founder of Outcomes4Me
Maya Said is the Founder and CEO of Outcomes4Me.
Follow Maya R. Said:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Daniel Vlock
Founder and CEO of Alopexx Enterprises
Dr. Vlock is founder and CEO of Alopexx Enterprises, LLC, a healthcare company focused on investing and developing preclinical and early clinical compounds. He is also CEO of Alopexx Pharmaceuticals, which developed a human monoclonal antibody directed against S. aureus. That antibody has completed a Phase 1 clinical trial and was licensed to Sanofi-Aventis. Dr. Vlock has held senior-level medical and research positions at Ariad Pharmaceuticals, GPC Biotech, Inc., and Pharmacia Corporation, where he ran the Celebrex Oncology Group and was responsible for this compound becoming the first drug approved for cancer prevention.
Follow Daniel Vlock:
About Alopexx Enterprises, Alopexx Enterprises, Alopexx Enterprises, Alopexx Enterprises: Alopexx partners with innovative entrepreneurs to build successful new companies. We will in-license novel therapies or medical devices
Michael Schrader
Co-Founder & CEO of Vaxess Technologies
Michael Schrader is the CEO and co-founder of Vaxess Technologies, a company revolutionizing global health by creating heat-stable vaccines. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world. The company was the winner of the 2013 MassTLC Innovative Life Science Technology of the Year, 2012 Harvard Business Plan Competition and The 2012 Harvard President’s Challenge for Social Entrepreneurship. Prior to founding Vaxess, Michael worked at Google, Toyota, and Honda where he has earned fifteen patents. He holds a BSME from Purdue University and an MBA from Harvard Business School.
Follow Michael Schrader:
About Harvard University, MassChallenge, Vaxess Technologies: Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Brooke Wurst
CEO/Founder of Harbor Biometrics
Follow Brooke Wurst:
About Harbor Biometrics, Remote Harbor, The TRIAD Trust: We make FirstID, the private vital health registry enabling emergency care providers to access life and cost saving info via biometric ID.
